adsilico is developing an end-to-end in-silico trials solution based on virtual ‘synthetic patient populations that will provide better and safer medical devices earlier to patients, reduce costs and accelerate R&D timescales for medical device developers, contribute to animal welfare by reducing animal experimentation, reducing refining and partially replacing costly and potentially harmful human trials.
